Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
This biotech stock looks like a great candidate to buy on the admittedly steep dip.
Overview
Go back to July 8, 2026. Ionis Pharmaceuticals (NASDAQ: IONS) was on a roll. The biotech stock had more than doubled over the previous 12 months. Its future looked bright. But one day later, everything changed.
Ionis lost more than 20% of its value on July 9. And that was just the beginning of the sell-off. Even with a rebound in recent days, the stock remains roughly 30% below its peak in early July.
Details
Was Ionis Pharmaceuticals' sell-off overdone? I think so.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.